Considering the immunostimulatory and anti-tumor effects of type I IFN responses, including innate immune activation, increased antigen presentation, immune cell infiltration, and tumor specific CD8 + T cell activation8–10, STING has been actively pursued as a target for cancer immunotherapy. This evidence concerns the gene STING1 and cancer.